The ethics of screening for disease

Pathology

Volumn 44, Issue 2, 2012, Pages 63-68

  Delatycki, Martin B ^a,b  

^a MURDOCH CHILDREN'S RESEARCH INSTITUTE   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

Autonomy; Consent; Equity of access; Ethics; Screening; Utility

Indexed keywords

EID: 84858314364     PISSN: 00313025     EISSN: 14653931     Source Type: Journal    
DOI: 10.1097/PAT.0b013e32834e8496     Document Type: Article

References (45)

1. Wilson J, Jungner G. The Principles and Practice of Screening for Disease. Public Health Paper 34. Geneva: World Health Organization, 1968.
2. Andermann A, Blancquaert I, Beauchamp S, Dery V. Revisiting Wilson and Jungner in the genomic era: a review of screening criteria over the past 40 years. Bull World Health Organ 2008; 86: 317-9. (Pubitemid 351521860)
3. Delatycki MB. Population screening for reproductive risk for single gene disorders in Australia: now and the future. Twin Res Hum Genet 2008; 11: 422-30.
4. Slater DN. Are women sufficiently well informed to provide valid consent for the cervical smear test? Cytopathology 2000; 11: 166-70. (Pubitemid 30409297)
5. Slaytor EK, Ward JE. How risksofbreast cancer and benefitsofscreening are communicated towomen: analysis of 58 pamphlets. BMJ 1998; 317: 263-4. (Pubitemid 28334155)
6. Ahmed S, Green J, Hewison J. Antenatal thalassaemia carrier testing: women's perceptions of 'information' and 'consent'. J Med Screen 2005; 12: 69-77. (Pubitemid 40835137)
7. Tsianakas V, Atkin K, Calnan MW, Dormandy E, Marteau TM. Offering antenatal sickle cell and thalassaemia screening to pregnant women in primary care: a qualitative study of women's experiences and expectations of participation. Health Expect 2011; Mar 3: Epub ahead of print.
8. Ilic D, O'Connor D, Green S, Wilt TJ. Screening for prostate cancer: an updated Cochrane systematic review. BJU Int 2011; 107: 882-91.
9. Witt D, Wold C, Louie E, Goonewardena P. Cystic fibrosis prenatal screening of over 50,000 members in a large HMO. Program update with an emphasis on the outcomes of high-risk pregnancies, reduction in the incidence of CF, and clinical utility. American Society of Human Genetics, Annual Scientific Meeting, 2003 (Abstract 255).
10. Brady RO. Enzyme replacement for lysosomal diseases. Annu Rev Med 2006; 57: 283-96. (Pubitemid 43261992)
11. Zuckerman S, Lahad A, Shmueli A, et al. Carrier screening for Gaucher disease: lessons for low-penetrance, treatable diseases. JAMA 2007; 298: 1281-90. (Pubitemid 47443342)
12. Watson MS, Cutting GR, Desnick RJ, et al. Cystic fibrosis population carrier screening: 2004 revision of American College of Medical Genetics mutation panel. Genet Med 2004; 6: 387-91. (Pubitemid 39310514)
13. Human Genetics Society of Australia. Cystic Fibrosis Population Screening Position Paper. November 2010 (cited May 2011). https://www.hgsa.org. au/website/wp-content/uploads/2010/06/2010PS02-CYSTIC-FIBROSIS-POPULATION- SCREENING.pdf
14. Graham JD, Corso PS, Morris JM, et al. Evaluating the cost-effectiveness of clinical and public health measures. Annu Rev Public Health 1998; 19: 125-52. (Pubitemid 28279927)
15. McKneally MF, Dickens BM, Meslin EM, Singer PA. Bioethics for clinicians: 13. Resource allocation. CMAJ 1997; 157: 163-7. (Pubitemid 27348222)
16. Savulescu J. Is current practice around late termination of pregnancy eugenic and discriminatory? Maternal interests and abortion. J Med Ethics 2001; 27: 165-71. (Pubitemid 32982847)
17. Dresser R. Prenatal testing and disability: a truce in the culture wars? Hastings Cent Rep 2009; 39: 7-8.
18. Skotko BG. Prenatally diagnosed Down syndrome: mothers who continued their pregnancies evaluate their health care providers. Am J Obstet Gynecol 2005; 192: 670-7. (Pubitemid 40311255)
19. Frumkin A, Zlotogora J. Genetic screening for reproductive purposes at school: is it a good strategy? Am J Med Genet A 2008; 146: 264-9.
20. Ross LF. Heterozygote carrier testing in high schools abroad: what are the lessons for the US? J Law Med Ethics 2006; 34: 753-64. (Pubitemid 44787838)
21. Gason AA, Delatycki MB, Metcalfe SA, Aitken M. It's 'back to school' for genetic screening. Eur J Hum Genet 2006; 14: 384-9.
22. Shakespeare T. Choices and rights: eugenics, genetics and disability equality. Disabil Soc 1998; 13: 665-81. (Pubitemid 128541153)
23. Tankard-Reist M. Defiant Birth: Women Who Resist Eugenics. Melbourne: Spinifex Press, 2006.
24. Markel H. The stigma of disease: implications of genetic screening. Am J Med 1992; 93: 209-15.
25. Borry P, Fryns JP, Schotsmans P, Dierickx K. Attitudes towards carrier testing in minors: a systematic review. Genet Couns 2005; 16: 341-52.
26. Borry P, Fryns JP, Schotsmans P, Dierickx K. Carrier testing in minors: a systematic review of guidelines and position papers. Eur J Hum Genet 2006; 14: 133-8. (Pubitemid 43135853)
27. Allen KJ, Gurrin LC, Constantine CC, et al. Iron-overload-related disease in HFE hereditary hemochromatosis. N Engl J Med 2008; 358: 221-30.
28. Bacon BR. Screening for hemochromatosis. Arch Intern Med 2006; 166: 269-70. (Pubitemid 43244313)
29. Haddow JE, Bradley LA. Hereditary haemochromatosis: to screen or not. Conditions for screening are not yet fulfilled. BMJ 1999; 319: 531-2.
30. Whitlock EP, Garlitz BA, Harris EL, et al. Screening for hereditary hemochromatosis: a systematic review for the US Preventive Services Task Force. Ann Intern Med 2006; 145: 209-23. (Pubitemid 46780566)
31. Cadet E, Capron D, Gallet M, et al. Reverse cascade screening of newborns for hereditary haemochromatosis: a model for other late onset diseases. J Med Genet 2005; 42: 390-5. (Pubitemid 40685679)
32. Delatycki MB, Allen KJ. In response to Cadet et al. J Med Genet 2006; 43: e3.
33. Delatycki MB, Allen KJ, Nisselle AE, et al. Use of community genetic screening to prevent HFE-associated hereditary haemochromatosis. Lancet 2005; 366: 314-6. (Pubitemid 41019421)
34. Delatycki M, Allen K, Williamson R. Insurance agreement to facilitate genetic testing. Lancet 2002; 359: 1433. (Pubitemid 34442391)
35. Keogh LA, van Vliet CM, Studdert DM, et al. Is uptake of genetic testing for colorectal cancer influenced by knowledge of insurance implications? Med J Aust 2009; 191: 255-8.
36. Grosse SD, Rogowski WH, Ross LF, et al. Population screening for genetic disorders in the 21st century: evidence, economics, and ethics. Public Health Genomics 2010; 13: 106-15.
37. National Health and Medical Research Council (NHMRC). Medical Genetic Testing: Information for Health Professionals. Canberra: NHMRC, 2010. http://www.nhmrc.gov.au/-files-nhmrc/publications/attachments/e99.pdf.
38. Dhondt JL. Implementation of informed consent for a cystic fibrosis newborn screening program in France: low refusal rates for optional testing. J Pediatr 2005; 147: S106-8.
39. Massie J, Forbes R, Dusart D, et al. Community-wide screening for cystic fibrosis carriers could replace newborn screening for the diagnosis of cystic fibrosis. J Paediatr Child Health 2007; 43: 721-3. (Pubitemid 47537624)
40. Hayes IM, Collins V, Sahhar M, et al. Newborn screening for mucopoly-saccharidoses: opinions of patients and their families. Clin Genet 2007; 71: 446-50. (Pubitemid 46730654)
41. Parsons EP, Clarke AJ, Hood K, et al. Newborn screening for Duchenne muscular dystrophy: a psychosocial study. Arch Dis Child Fetal Neonatal Ed 2002; 86: F91-5. (Pubitemid 34250885)
42. Pass KA, Lane PA, Fernhoff PM, et al. US newborn screening system guidelines II: follow-up of children, diagnosis, management, and evaluation. Statement of the Council of Regional Networks for Genetic Services (CORN). J Pediatr 2000; 137: S1-46.
43. Borry P, Nys H, Dierickx K. Carrier testing in minors: conflicting views. Nat Rev Genet 2007; 8: 828. (Pubitemid 47609094)
44. Fernhoff PM. Newborn screening for genetic disorders. Pediatr Clin North Am 2009; 56: 505-13.
45. Couzin-Frankel J. Newborn blood collections. Science gold mine, ethical minefield. Science 2009; 324: 166-8.